세계의 희귀질환 시장(2024-2034년)

The global Rare Diseases market is projected to grow at a CAGR of 8.8% by 2034

The Rare Diseases Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Advancements in R&D and Regulatory Incentives Driving Market Growth

The rare diseases market is driven by a convergence of factors that collectively shape its growth trajectory and impact. One pivotal driver is the increasing awareness and understanding of rare diseases among healthcare professionals, policymakers, and the general public. This heightened awareness leads to earlier diagnosis, improved access to treatment, and expanded support networks for patients and families.

Advancements in research and development, fuelled by both public and private investment, continuously expand the therapeutic landscape for rare diseases. Breakthroughs in areas such as gene therapy, precision medicine, and orphan drug development hold promise for addressing previously unmet medical needs.

Regulatory incentives and policies that encourage innovation and investment play a significant role in driving the rare diseases market forward. These include extended market exclusivity, expedited review processes, and financial incentives for drug development. Furthermore, the globalization of healthcare and the emergence of new markets, particularly in developing countries, present opportunities for market expansion and access to rare disease treatments. Collectively, these driving factors underscore the dynamic and multifaceted nature of the rare diseases market, fuelled by a commitment to improving outcomes for patients facing these challenging conditions.

High Entry Barriers Likely to Challenge Industry Growth

High entry barriers pose a significant challenge to the growth of the rare diseases market. The substantial costs and lengthy timelines associated with research and development deter new entrants, limiting competition and innovation. Additionally, stringent regulatory requirements and complex reimbursement processes further hinder market entry for potential therapies. These barriers create a formidable challenge for companies seeking to develop and commercialize treatments for rare diseases, constraining market growth and potentially limiting patient access to new therapies.

What Questions Should You Ask before Buying a Market Research Report?

How is the rare diseases market evolving?

What is driving and restraining the rare diseases market?

How will each rare diseases submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each rare diseases submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading rare diseases markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the rare diseases projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of rare diseases projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the rare diseases market?

Where is the rare diseases market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the rare diseases market today, and over the next 10 years:

Our 344-page report provides 126 tables, 185 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising rare diseases prices and recent developments.

Segments Covered in the Report

Diseases

Cancer

Metabolic Diseases

Neurological Conditions

Hematologic Disorders

Infectious Diseases

Musculoskeletal Disorders

Cardiovascular Disorders

Others

Type

Non Biologics

Biologics

End-users

Specialty Pharmacies

Hospital Pharmacies

Retail Pharmacies

Age Group

Adult

Pediatric

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Netherlands

Switzerland

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Malaysia

Singapore

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Rare Diseases Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

Alexion Pharmaceuticals, Inc. (AstraZeneca)

Amgen Inc.

Amneal Pharmaceuticals LLC

Biogen Inc.

Bristol-Myers Squibb Company

Chiesi Farmaceutici S.p.A.

Dr. Reddy's Laboratories Ltd.

F. Hoffmann-La Roche Ltd.

Johnson & Johnson Services, Inc.

Merck & Co Inc.

Novartis AG

Pfizer Inc.

Sanofi

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Vertex Pharmaceuticals Incorporated

Overall world revenue for Rare Diseases Market, 2024 to 2034 in terms of value the market will surpass US$200.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Rare Diseases Market, 2024 to 2034 report help you?

In summary, our 340+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Rare Diseases Market, 2024 to 2034, with forecasts for disease, type, end-users, and age group each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 25 key national markets - See forecasts for the Rare Diseases Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 17 of the major companies involved in the Rare Diseases Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Rare Diseases Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Rare Diseases Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Increasing Number of Drug Approvals
    • 3.3.1.2 Robust Pipeline by Major Players
    • 3.3.1.3 Increasing Awareness Regarding Rare Diseases
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 High Research and Development Cost
    • 3.3.2.2 High Entry Barriers to Challenge Market Growth
    • 3.3.2.3 Limited Patient Population
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Increasing Demand from Emerging Economies
    • 3.3.3.2 Increasing Government Support
    • 3.3.3.3 Advancement in Research and Development
• 3.4 Regulatory Framework
• 3.5 Emerging Markets and Megatrends
• 3.6 Porter's Five Forces Analysis
  • 3.6.1 Bargaining Power of Suppliers
  • 3.6.2 Bargaining Power of Buyers
  • 3.6.3 Competitive Rivalry
  • 3.6.4 Threat from Substitutes
  • 3.6.5 Threat of New Entrants
• 3.7 PEST Analysis
  • 3.7.1 Political
  • 3.7.2 Economical
  • 3.7.3 Social
  • 3.7.4 Technological
• 3.8 Pipeline Analysis

4 Rare Diseases Market Analysis by Disease

• 4.1 Key Findings
• 4.2 Disease Segment: Market Attractiveness Index
• 4.3 Rare Diseases Market Size Estimation and Forecast by Disease
• 4.4 Cancer
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Metabolic Diseases
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.6 Neurological Conditions
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)
• 4.7 Hematological Disorders
  • 4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.7.2 Market Share by Region, 2024 & 2034 (%)
• 4.8 Infectious Diseases
  • 4.8.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.8.2 Market Share by Region, 2024 & 2034 (%)
• 4.9 Musculoskeletal Disorders
  • 4.9.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.9.2 Market Share by Region, 2024 & 2034 (%)
• 4.10 Cardiovascular Disorders
  • 4.10.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.10.2 Market Share by Region, 2024 & 2034 (%)
• 4.11 Others
  • 4.11.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.11.2 Market Share by Region, 2024 & 2034 (%)

5 Rare Diseases Market Analysis by Type

• 5.1 Key Findings
• 5.2 Type Segment: Market Attractiveness Index
• 5.3 Rare Diseases Market Size Estimation and Forecast by Type
• 5.4 Non Biologics
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Biologics
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)

6 Rare Diseases Market Analysis by End-users

• 6.1 Key Findings
• 6.2 End-users Segment: Market Attractiveness Index
• 6.4 Rare Diseases Market Size Estimation and Forecast by End-users
• 6.5 Specialty Pharmacies
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)
• 6.6 Hospital Pharmacies
  • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.6.2 Market Share by Region, 2024 & 2034 (%)
• 6.7 Retail Pharmacies
  • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.7.2 Market Share by Region, 2024 & 2034 (%)

7 Rare Diseases Market Analysis by Age Group

• 7.1 Key Findings
• 7.2 Age Group Segment: Market Attractiveness Index
• 7.4 Rare Diseases Market Size Estimation and Forecast by Age Group
• 7.5 Adult
  • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.5.2 Market Share by Region, 2024 & 2034 (%)
• 7.6 Pediatric
  • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Rare Diseases Market Analysis by Region

• 8.1 Key Findings
• 8.3 Regional Market Size Estimation and Forecast

9 North America Rare Diseases Market Analysis

• 9.1 Key Findings
• 9.2 North America Rare Diseases Market Attractiveness Index
• 9.3 North America Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 9.4 North America Rare Diseases Market Size Estimation and Forecast by Country
• 9.5 North America Rare Diseases Market Size Estimation and Forecast by Disease
• 9.6 North America Rare Diseases Market Size Estimation and Forecast by Type
• 9.7 North America Rare Diseases Market Size Estimation and Forecast by End-users
• 9.8 North America Rare Diseases Market Size Estimation and Forecast by Age Group
• 9.9 U.S. Rare Diseases Market Analysis
• 9.10 Canada Rare Diseases Market Analysis

10 Europe Rare Diseases Market Analysis

• 10.1 Key Findings
• 10.2 Europe Rare Diseases Market Attractiveness Index
• 10.3 Europe Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 10.4 Europe Rare Diseases Market Size Estimation and Forecast by Country
• 10.5 Europe Rare Diseases Market Size Estimation and Forecast by Disease
• 10.6 Europe Rare Diseases Market Size Estimation and Forecast by Type
• 10.7 Europe Rare Diseases Market Size Estimation and Forecast by End-users
• 10.8 Europe Rare Diseases Market Size Estimation and Forecast by Age Group
• 10.9 Germany Rare Diseases Market Analysis
• 10.10 UK Rare Diseases Market Analysis
• 10.11 France Rare Diseases Market Analysis
• 10.12 Italy Rare Diseases Market Analysis
• 10.13 Spain Rare Diseases Market Analysis
• 10.14 Netherlands Rare Diseases Market Analysis
• 10.15 Switzerland Rare Diseases Market Analysis
• 10.16 Rest of Europe Rare Diseases Market Analysis

11 Asia Pacific Rare Diseases Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Rare Diseases Market Attractiveness Index
• 11.3 Asia Pacific Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 11.4 Asia Pacific Rare Diseases Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Rare Diseases Market Size Estimation and Forecast by Disease
• 11.6 Asia Pacific Rare Diseases Market Size Estimation and Forecast by Type
• 11.7 Asia Pacific Rare Diseases Market Size Estimation and Forecast by End-users
• 11.8 Asia Pacific Rare Diseases Market Size Estimation and Forecast by Age Group
• 11.9 Japan Rare Diseases Market Analysis
• 11.10 China Rare Diseases Market Analysis
• 11.11 India Rare Diseases Market Analysis
• 11.12 Australia Rare Diseases Market Analysis
• 11.13 South Korea Rare Diseases Market Analysis
• 11.14 Malaysia Rare Diseases Market Analysis
• 11.15 Singapore Rare Diseases Market Analysis
• 11.16 Rest of Asia Pacific Rare Diseases Market Analysis

12 Latin America Rare Diseases Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Rare Diseases Market Attractiveness Index
• 12.3 Latin America Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 12.4 Latin America Rare Diseases Market Size Estimation and Forecast by Country
• 12.5 Latin America Rare Diseases Market Size Estimation and Forecast by Disease
• 12.6 Latin America Rare Diseases Market Size Estimation and Forecast by Type
• 12.7 Latin America Rare Diseases Market Size Estimation and Forecast by End-users
• 12.8 Latin America Rare Diseases Market Size Estimation and Forecast by Age Group
• 12.9 Brazil Rare Diseases Market Analysis
• 12.10 Mexico Rare Diseases Market Analysis
• 12.11 Argentina Rare Diseases Market Analysis
• 12.12 Rest of Latin America Rare Diseases Market Analysis

13 MEA Rare Diseases Market Analysis

• 13.1 Key Findings
• 13.2 MEA Rare Diseases Market Attractiveness Index
• 13.3 MEA Rare Diseases Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 13.4 MEA Rare Diseases Market Size Estimation and Forecast by Country
• 13.5 MEA Rare Diseases Market Size Estimation and Forecast by Disease
• 13.6 MEA Rare Diseases Market Size Estimation and Forecast by Type
• 13.7 MEA Rare Diseases Market Size Estimation and Forecast by End-users
• 13.8 MEA Rare Diseases Market Size Estimation and Forecast by Age Group
• 13.9 GCC Rare Diseases Market Analysis
• 13.10 South Africa Rare Diseases Market Analysis
• 13.11 Rest of MEA Rare Diseases Market Analysis

14 Company Profiles

• 14.1 Competitive Landscape, 2023
• 14.2 Novartis AG
  • 14.2.1 Company Snapshot
  • 14.2.2 Company Overview
  • 14.2.3 Financial Analysis
    • 14.2.3.1 Net Revenue, 2019-2023
    • 14.2.3.2 Regional Market Shares, 2023
    • 14.2.3.3 R&D Expense, 2019-2023
  • 14.2.5 Product Benchmarking
  • 14.2.6 Strategic Outlook
• 14.3 Teva Pharmaceutical Industries Ltd.
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Revenue, 2019-2023
    • 14.3.3.2 Regional Market Shares, 2023
    • 14.3.3.3 R&D Expense, 2019-2023
  • 14.3.4 Product Benchmarking
  • 14.3.5 Strategic Outlook
• 14.4 AbbVie Inc.
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
    • 14.4.3.1 Revenue, 2019-2023
    • 14.4.3.2 Regional Market Shares, 2023
    • 14.4.3.3 R&D Expense, 2019-2023
  • 14.4.4 Product Benchmarking
• 14.5 Alexion Pharmaceuticals, Inc. (AstraZeneca)
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Product Benchmarking
  • 14.5.4 Strategic Outlook
• 14.6 Amgen Inc.
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Net Revenue, 2019-2023
    • 14.6.3.2 Regional Market Shares, 2023
    • 14.6.3.3 R&D Expense, 2019-2023
  • 14.6.4 Product Benchmarking
  • 14.6.5 Strategic Outlook
• 14.7 Biogen Inc.
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Revenue, 2019-2023
    • 14.7.3.2 Regional Market Shares, 2023
    • 14.7.3.3 R&D Expense, 2019-2023
  • 14.7.4 Product Benchmarking
  • 14.7.5 Strategic Outlook
• 14.8 F. Hoffmann-La Roche Ltd.
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Financial Analysis
    • 14.8.3.1 Revenue, 2019-2023
    • 14.8.3.2 Regional Market Shares, 2023
    • 14.8.3.3 R&D Expense, 2019-2023
  • 14.8.4 Product Benchmarking
  • 14.8.5 Strategic Outlook
• 14.9 Johnson & Johnson Services, Inc.
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
    • 14.9.3.1 Revenue, 2019-2023
    • 14.9.3.2 Regional Market Shares, 2023
    • 14.9.3.3 R&D Expense, 2019-2023
  • 14.9.5 Product Benchmarking
  • 14.9.6 Strategic Outlook
• 14.10 Merck & Co Inc.
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Financial Analysis
    • 14.10.3.1 Revenue, 2019-2023
    • 14.10.3.2 Regional Market Shares, 2023
    • 14.10.3.3 R&D Expense, 2019-2023
  • 14.10.5 Product Benchmarking
• 14.11 Pfizer Inc.
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Revenue, 2019-2023
    • 14.11.3.2 Regional Market Shares, 2023
    • 14.11.3.3 R&D Expense, 2019-2023
  • 14.11.5 Product Benchmarking
  • 14.11.6 Strategic Outlook
• 14.12 Sanofi
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Financial Analysis
    • 14.12.3.1 Revenue, 2019-2023
    • 14.12.3.2 Regional Market Shares, 2023
    • 14.12.3.3 R&D Expense, 2019-2023
  • 14.12.5 Product Benchmarking
• 14.13 Takeda Pharmaceutical Company Limited.
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Financial Analysis
    • 14.13.3.1 Revenue, 2019-2023
    • 14.13.3.2 R&D Expense, 2018-2022
  • 14.13.4 Product Benchmarking
  • 14.13.5 Strategic Outlook
• 14.14 Bristol-Myers Squibb Company
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Financial Analysis
    • 14.14.3.1 Revenue, 2019-2023
    • 14.14.3.2 Regional Market Shares, 2023
    • 14.14.3.3 R&D Expense, 2019-2023
  • 14.14.4 Product Benchmarking
  • 14.14.5 Strategic Outlook
• 14.15 Amneal Pharmaceuticals LLC
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Financial Analysis
    • 14.15.3.1 Revenue, 2018-2022
    • 14.15.3.2 R&D Expense, 2018-2022
  • 14.15.4 Product Benchmarking
  • 14.15.5 Strategic Outlook
• 14.16 Dr. Reddy's Laboratories Ltd.
  • 14.16.1 Company Snapshot
  • 14.16.2 Company Overview
  • 14.16.3 Financial Analysis
    • 14.16.3.1 Revenue, 2019-2023
    • 14.16.3.2 Regional Market Shares, 2022
    • 14.16.3.3 R&D Expense, 2018-2022
  • 14.16.4 Product Benchmarking
  • 14.16.5 Strategic Outlook
• 14.17 Chiesi Farmaceutici S.p.A.
  • 14.17.1 Company Snapshot
  • 14.17.2 Company Overview
  • 14.17.3 Product Benchmarking
  • 14.17.4 Strategic Outlook
• 14.18 Vertex Pharmaceuticals Incorporated
  • 14.18.1 Company Snapshot
  • 14.18.2 Company Overview
  • 14.18.3 Financial Analysis
    • 14.18.3.1 Revenue, 2019-2023
    • 14.18.3.2 Regional Market Shares, 2023
    • 14.18.3.3 R&D Expense, 2019-2023
  • 14.18.4 Product Benchmarking
  • 14.18.5 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players